Literature DB >> 12957406

A specific ELISA for measuring neurofilament heavy chain phosphoforms.

A Petzold1, G Keir, A J E Green, G Giovannoni, E J Thompson.   

Abstract

Neurofilaments (Nf) are the major constitutents of the axoskeleton and body fluid Nf levels are an important tool for estimating axonal degeneration in vivo. This paper presents a new sandwich ELISA allowing quantification of the NfH(SMI35) phosphoform from CSF, brain tissue and cell culture homogenates. The sensitivity of the NfH(SMI35) ELISA is 0.2 ng/ml with a recovery of 119% and a mean within- and between-batch precision of 10.6% and 23%, respectively. CSF NfH(SMI35) was stable at 4 degrees C, is not influenced by freeze-thaw cycles, and proteolysis present at room temperature could be prevented by adding protease inhibitors. Aggregate formation was observed for HPLC-purified bovine NfH and could be resolved by sonication. The upper reference value for CSF NfH(SMI35) levels (0.73 ng/ml) was defined as the 95% cumulative frequency from 416 CSF samples. Based on this cutoff, a significantly higher proportion of patients with amyotrophic lateral sclerosis, space-occupying lesions, disc prolapse and subarachnoid haemorrhage had pathologically elevated NfH(SMI35) levels compared to patients with cluster headache or demyelinating disease.A new nomenclature is proposed to facilitate the comparison between ELISA, immunoblotting and immunocytochemistry.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12957406     DOI: 10.1016/s0022-1759(03)00189-3

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  46 in total

1.  Rostrocaudal dynamics of CSF biomarkers.

Authors:  Andrew Tarnaris; Ahmed K Toma; Miles D Chapman; Axel Petzold; Geoff Keir; Neil D Kitchen; Laurence D Watkins
Journal:  Neurochem Res       Date:  2010-12-30       Impact factor: 3.996

2.  Axonal damage accumulates in the progressive phase of multiple sclerosis: three year follow up study.

Authors:  A Petzold; M J Eikelenboom; G Keir; D Grant; R H C Lazeron; C H Polman; B M J Uitdehaag; E J Thompson; G Giovannoni
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-02       Impact factor: 10.154

3.  Protein aggregate formation permits millennium-old brain preservation.

Authors:  Axel Petzold; Ching-Hua Lu; Mike Groves; Johan Gobom; Henrik Zetterberg; Gerry Shaw; Sonia O'Connor
Journal:  J R Soc Interface       Date:  2020-01-08       Impact factor: 4.118

Review 4.  Review on intermediate filaments of the nervous system and their pathological alterations.

Authors:  Claire Lépinoux-Chambaud; Joël Eyer
Journal:  Histochem Cell Biol       Date:  2013-06-08       Impact factor: 4.304

5.  CSF neurofilament protein analysis in the differential diagnosis of ALS.

Authors:  Thierry S Reijn; Wilson F Abdo; Helenius J Schelhaas; Marcel M Verbeek
Journal:  J Neurol       Date:  2009-03-18       Impact factor: 4.849

6.  Biomarker evidence for mild central nervous system injury after surgically-induced circulation arrest.

Authors:  Robert Siman; Victoria L Roberts; Elizabeth McNeil; Antony Dang; Joseph E Bavaria; Sindhu Ramchandren; Michael McGarvey
Journal:  Brain Res       Date:  2008-04-01       Impact factor: 3.252

7.  A novel biomarker for retinal degeneration: vitreous body neurofilament proteins.

Authors:  Axel Petzold; Anselm Junemann; Konrad Rejdak; Tomasz Zarnowski; Sebastian Thaler; Pawel Grieb; Friedrich E Kruse; Eberhart Zrenner; Robert Rejdak
Journal:  J Neural Transm (Vienna)       Date:  2009-09-22       Impact factor: 3.575

Review 8.  ALS biomarkers for therapy development: State of the field and future directions.

Authors:  Michael Benatar; Kevin Boylan; Andreas Jeromin; Seward B Rutkove; James Berry; Nazem Atassi; Lucie Bruijn
Journal:  Muscle Nerve       Date:  2015-12-29       Impact factor: 3.217

Review 9.  Neurofilaments in disease: what do we know?

Authors:  Brian A Gordon
Journal:  Curr Opin Neurobiol       Date:  2020-03-06       Impact factor: 6.627

Review 10.  Cerebrospinal fluid biomarkers in Guillain-Barré syndrome--where do we stand?

Authors:  Johannes Brettschneider; Axel Petzold; Sigurd Süssmuth; Hayrettin Tumani
Journal:  J Neurol       Date:  2009-02-16       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.